文献速递甲状腺疾病

RET融合阳性与BRAFV600E阳性甲状腺乳头状癌的临床与超声特征差异

Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

回顾性纳入2021年8月至2024年1月诊断的209例甲状腺乳头状癌患者,其中RET融合30例、BRAFV600E 179例,比较两组临床与超声特征。RET融合组年龄更小、肿瘤更大、N分期更晚,超声以不均匀回声、边界不清、形态不规则及结节内微钙化为主,并可见散在微钙化。多因素分析显示散在微钙化为RET融合阳性患者侧颈淋巴结转移的独立危险因素(OR 9.79,95%CI 1.31-72.93,P=.026)。

要点

  • RET融合阳性甲状腺乳头状癌较BRAFV600E阳性者年龄更小、肿瘤更大、N分期更晚。
  • RET融合阳性超声以边界不清(90.0%)、形态不规则(83.3%)、结节内微钙化(83.3%)多见。
  • 散在微钙化是RET融合阳性患者侧颈淋巴结转移的独立危险因素(OR 9.79)。

核心结论

  • RET融合阳性甲状腺乳头状癌具有独特的临床特征与超声表现,超声检查可作为RET融合诊断的术前无创初筛方法,有助于筛选患者进行针对性分子测序以改善治疗结局。

研究设计与样本

  • 回顾性研究纳入2021年8月至2024年1月诊断的209例甲状腺乳头状癌患者,均接受超声检查并经病理证实为RET融合或BRAFV600E阳性。

主要发现

  • 全部209例中检出RET融合30例、BRAFV600E 179例。
  • RET融合组年龄38.5(16.0-69.0)岁 vs BRAFV600E组42.9(20.0-74.0)岁,P<.05。
  • RET融合组肿瘤大小1.09(0.5-4.0)cm vs BRAFV600E组0.77(0.1-4.0)cm,P<.005。
  • RET融合组N分期较BRAFV600E组更晚(P<.001)。
  • RET融合组超声主要表现为不均匀回声(43.3%)、边界不清(90.0%)、形态不规则(83.3%)、结节内微钙化(83.3%),并以肿瘤周围/甲状腺内散在微钙化为特征(40.0%);BRAFV600E组主要表现为低回声(95.5%)、圆形/椭圆形(80.4%)、结节内无钙化(54.2%)。

关键数值与推荐

  • RET融合阳性甲状腺乳头状癌超声特征:不均匀回声43.3%、边界不清90.0%、形态不规则83.3%、结节内微钙化83.3%、肿瘤周围/甲状腺内散在微钙化40.0%。
  • BRAFV600E阳性甲状腺乳头状癌超声特征:低回声95.5%、圆形/椭圆形80.4%、结节内无钙化54.2%。

临床怎么用

  • 作者认为超声检查可提供RET融合诊断的术前无创初筛方法,有助于筛选患者进行针对性分子测序以改善治疗结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to describe the ultrasound characteristics of papillary thyroid carcinoma (PTC) harboring RET gene fusion and explore its clinical significance. METHODS: A retrospective study was conducted on 209 patients with PTC diagnosed between August 2021 and January 2024. All patients underwent ultrasound examination and were confirmed to be positive for RET fusion or BRAFV600E by pathological results. The differences in clinical characteristics and ultrasonography features between the 2 groups were analyzed. RESULTS: Among all PTCs (n = 209), we detected 30 RET fusions and 179 BRAFV600E. RET-fusion PTCs showed younger age [38.5 (16.0-69.0) vs 42.9 (20.0-74.0) years, P < .05], larger tumor size [1.09 (0.5-4.0) vs 0.77 (0.1-4.0) cm, P < .005], and more advanced N stage (P < .001) than BRAFV600E PTCs. RET-fusion PTCs were mainly classical and diffuse sclerosing subtypes. In terms of ultrasound performance, RET-fusion PTCs were mainly manifested as heterogeneous echogenicity (43.3%), ill-defined tumor margin (90.0%), irregular shape (83.3%), and intranodular microcalcification (83.3%), characterized by scattered microcalcification around the tumor/within thyroid gland (40.0%). In comparison, BRAFV600E PTCs were mainly characterized by hypoechogenicity (95.5%), round/oval shape (80.4%), and intranodular noncalcification (54.2%). Multivariate logistic regression analysis revealed that scattered microcalcification around the tumor/within the normal gland was an independent risk factor for lateral lymph node metastasis (LLNM) in RET-fusion PTCs (odds ratio 9.79, 95% confidence interval 1.31-72.93, P = .026). CONCLUSION: Patients diagnosed with PTC harboring RET fusion presented with distinctive clinical characteristics and sonographic patterns, underscoring the unique diagnostic value of ultrasound examination. It can provide a preoperative noninvasive primary screening method for RET-fusion diagnosis, thus facilitating targeted patients with purposeful molecular sequencing to improve treatment outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chen Z, Sun W, Fei M, et al. Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2025. PMID: 39552056. doi:10.1210/clinem/dgae803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。